• 1. 第三軍醫(yī)大學(xué)西南醫(yī)院普通外科(重慶400038)2. 第三軍醫(yī)大學(xué)西南醫(yī)院病理學(xué)教研室;

為探討C-erb B-2基因變化在乳腺不典型增生癌變過程中的意義，檢測(cè)正常乳腺、乳腺囊性增生病不典型增生和乳腺癌細(xì)胞C-erb B-2基因產(chǎn)物表達(dá)。結(jié)果：正常乳腺上皮細(xì)胞和乳腺囊性增生病上皮細(xì)胞增生Ⅰ級(jí)者均無C-erb B-2癌基因蛋白表達(dá)；不典型增生Ⅱ、Ⅲ級(jí)和乳腺癌組織中C-erb B-2癌基因蛋白染色陽性率分別為20.0%、40.0%和54.2%。提示該基因的異常改變可發(fā)生于正常細(xì)胞經(jīng)不典型增生向癌細(xì)胞轉(zhuǎn)化期中，可能是部分不典型增生細(xì)胞異常增生的原因或促進(jìn)因素，是乳腺上皮細(xì)胞向惡性轉(zhuǎn)化的標(biāo)志之一。

引用本文： 姜軍,陳意生,馬宏敏,詹新恩,柳鳳軒. 乳腺不典型增生細(xì)胞C-erb B-2基因產(chǎn)物表達(dá)與乳腺癌發(fā)生的關(guān)系. 中國(guó)普外基礎(chǔ)與臨床雜志, 1998, 5(5): 257-259. doi: 復(fù)制

版權(quán)信息： ?四川大學(xué)華西醫(yī)院華西期刊社《中國(guó)普外基礎(chǔ)與臨床雜志》版權(quán)所有，未經(jīng)授權(quán)不得轉(zhuǎn)載、改編

1. Page DL. Cancer risk assessment in benign breast biopsies. Human Pathol, 1986; 17(8)∶871.
2. 李樹玲.乳腺癌.見：中華人民共和國(guó)醫(yī)政司編.中國(guó)常見惡性腫瘤診治規(guī)范(第八分冊(cè)).北京：北京醫(yī)科大學(xué)中國(guó)協(xié)和醫(yī)科大學(xué)出版社，1991∶25～58.
3. Gusterson BA, Gullick WJ, Venter DJ, et al. Immunohistochemical localization of Cerb B2 in human breast carcinomas. Mol Cell Probes, 1988; 2(1)∶383.
4. Slamon DJ, Clark GM, Wong SG, et al. Huamn breast cancer:correlation of relapse and survival with amplification of the HER2/neu oncogen. Science, 1987; 235(4785)∶177.
5. Bacus SS, Ruby SG, Weinberg DS, et al. HER2/neu oncoprotein expression and proliferation in breast cancer. Am J Pathol, 1990; 137(1)∶103.
6. 葉鋒，黃冰，黃書偉.乳腺腫瘤中Cerb B2癌基因產(chǎn)物的表達(dá)及意義.中華病理學(xué)雜志，1993； 22(2)∶104.
7. Hamna W, Kahn HJ, Andrulis I, et al. Distribution and patterns of staining of neu oncogene product in benign and malignant breast diseases. Mod Pathol, 1990; 3(4)∶455.
8. Lodato RF, Maguire HC, Greene MI, et al. Immunohistochemical evaluation of Cerb B2 oncogene expression in ductal carcinoma in situ and atypical ductal hyperplasia of breast. Mod Pathol, 1990; 3(4)∶449.
9. Ramachandra S, Machin L, Ashley S, et al. Immunohistochemical distribution of Cerb B2 in situ breast carcinoma: a detailed morphological analysis. J Pathol, 1990; 161(1)∶7.
  1. 1. Page DL. Cancer risk assessment in benign breast biopsies. Human Pathol, 1986; 17(8)∶871.
  2. 2. 李樹玲.乳腺癌.見：中華人民共和國(guó)醫(yī)政司編.中國(guó)常見惡性腫瘤診治規(guī)范(第八分冊(cè)).北京：北京醫(yī)科大學(xué)中國(guó)協(xié)和醫(yī)科大學(xué)出版社，1991∶25～58.
  3. 3. Gusterson BA, Gullick WJ, Venter DJ, et al. Immunohistochemical localization of Cerb B2 in human breast carcinomas. Mol Cell Probes, 1988; 2(1)∶383.
  4. 4. Slamon DJ, Clark GM, Wong SG, et al. Huamn breast cancer:correlation of relapse and survival with amplification of the HER2/neu oncogen. Science, 1987; 235(4785)∶177.
  5. 5. Bacus SS, Ruby SG, Weinberg DS, et al. HER2/neu oncoprotein expression and proliferation in breast cancer. Am J Pathol, 1990; 137(1)∶103.
  6. 6. 葉鋒，黃冰，黃書偉.乳腺腫瘤中Cerb B2癌基因產(chǎn)物的表達(dá)及意義.中華病理學(xué)雜志，1993； 22(2)∶104.
  7. 7. Hamna W, Kahn HJ, Andrulis I, et al. Distribution and patterns of staining of neu oncogene product in benign and malignant breast diseases. Mod Pathol, 1990; 3(4)∶455.
  8. 8. Lodato RF, Maguire HC, Greene MI, et al. Immunohistochemical evaluation of Cerb B2 oncogene expression in ductal carcinoma in situ and atypical ductal hyperplasia of breast. Mod Pathol, 1990; 3(4)∶449.
  9. 9. Ramachandra S, Machin L, Ashley S, et al. Immunohistochemical distribution of Cerb B2 in situ breast carcinoma: a detailed morphological analysis. J Pathol, 1990; 161(1)∶7.